Keita Mori
Co-Founder, President, Govt Officer, CEO & Consultant Director
Good afternoon. That is Keita Mori from SanBio, and thanks very a lot for coming to this quarterly replace assembly. Right this moment, I’ve 3 agendas. First agenda is the monetary outcomes. The second agenda is the progress within the first half yr 6 months. After which thirdly, I’ll go over future outlook.
So first, monetary outcomes, and I want to clarify the consolidated statements of earnings. In order we’re working to get acquiring approval of AKUUGO, this partial change approval, our spending sample has been fairly much like the final quarters or final yr or so. And this 6 months, we spent about JPY 1.8 billion, and this was primarily a element was the bills associated to actions for acquiring a partial change approval AKUUGO.
Now I would like to maneuver on to the steadiness sheet. As all the time, I would love everybody to have a look at the money and money equivalents to make sure the well being of — financial well being of our firm. We preserve a prudent degree of money and money equivalents. Particularly, we have now JPY 2.7 billion, and this meets our foreseeable short- to medium-term wants.
This time, we revised the consolidated earnings forecast. So I would like to spotlight this to our viewers. The first change is because of a rise in manufacturing-related bills and the intent right here is to safe stock of AKUUGO on the early stage. So in case you may have a look at this, the working expense, the unique plan or forecast was JPY 3.5 billion and now the revised forecast is at JPY 3.9 billion.
Now I would like
